No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GSK240705P36500
- 0.10
- +0.05+100.00%
15min DelayClose Jul 2 16:00 ET
0.10High0.07Low
0.07Open0.05Pre Close11 Volume16 Open Interest36.50Strike Price80.00Turnover46.56%IV4.74%PremiumJul 5, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1260Delta0.1320Gamma382.10Leverage Ratio-0.0542Theta-0.0004Rho-48.13Eff Leverage0.0070Vega
Intraday
- 5D
- Daily
News
Express News | GlaxoSmithKline and curevac have redrafted their mRNA vaccine collaboration agreement
Biggest Stock Movers Today: PARAA, CVAC, and More
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell
CureVac (CVAC) and GSK (GSK) said Wednesday that they have restructured their existing partnership into a new licensing agreement that will allow each company to prioritize investment and focus on the
GlaxoSmithKline (GSK.US) acquires control of multiple vaccine development programs from German partners involving up to €1.45 billion.
United Kingdom pharmaceutical giant glaxosmithkline (GSK.US) announced on Wednesday that it will rebuild its partnership with German biotech company curevac and take control of the joint development of multiple vaccines. GSK will pay CureVac an upfront payment of 400 million euros and up to an additional 1.05 billion euros for development/regulatory approval and sales milestones. The two companies have been working together since 2020 to develop a variety of infectious disease vaccines using messenger ribonucleic acid technology (mRNA). CureVac sold multiple vaccine development projects through this trade and obtained the upfront payment to provide
CureVac to Cut 30% of Workforce as GSK Buys Rights to Make Flu, Covid Shots
US stock market abnormal <strong>Curevac</strong> rose nearly 20% before the market, expanded the mRNA vaccine cooperation agreement with <strong>GlaxoSmithKline</strong>, and planed to cut 30% of staff.
On July 3, Gelunhui, CureVac (CVAC.US), a German vaccine company, rose nearly 20% before pre-market trading, reporting $4. On the news front, GlaxoSmithKline and CureVac have redrafted their mRNA vaccine collaboration agreement in a new licensing agreement, giving GlaxoSmithKline the full rights to develop flu and COVID-19 candidate vaccines (including combination vaccines). CureVac will receive a prepayment of 400 million euros, as well as up to 1.05 billion euros in milestones and royalties. In addition, CureVac has begun a global strategy reorganization plan, which includes a 30% reduction in staff.